Callan Family Office LLC Invests $434,000 in Repligen Co. (NASDAQ:RGEN)

Callan Family Office LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,016 shares of the biotechnology company’s stock, valued at approximately $434,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RGEN. Champlain Investment Partners LLC boosted its position in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares in the last quarter. Conestoga Capital Advisors LLC lifted its stake in shares of Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock valued at $136,395,000 after purchasing an additional 6,872 shares during the period. Thrivent Financial for Lutherans boosted its holdings in Repligen by 6.1% during the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after buying an additional 36,773 shares in the last quarter. DF Dent & Co. Inc. grew its position in Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after buying an additional 139,615 shares during the period. Finally, New York State Common Retirement Fund increased its holdings in Repligen by 2.5% in the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock valued at $83,693,000 after buying an additional 14,398 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Down 2.8 %

Shares of NASDAQ RGEN opened at $155.70 on Monday. The firm has a market cap of $8.72 billion, a P/E ratio of -305.29, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $203.13. The firm’s 50 day moving average price is $157.23 and its 200 day moving average price is $148.59.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, sell-side analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on RGEN shares. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. Royal Bank of Canada upped their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. TD Cowen started coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. Finally, Canaccord Genuity Group raised their target price on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.